AOD-9604 in Canada: What Researchers Need to Know About This Metabolic Peptide in 2026

Among the peptides generating consistent interest in metabolic research, AOD-9604 occupies a unique position. Derived from the C-terminal region of human growth hormone (hGH), this synthetic fragment has been studied for decades for its ability to influence fat metabolism — without the broader hormonal effects associated with full growth hormone. For Canadian researchers and academics with an interest in peptide science, AOD-9604 represents a compelling subject of study.

This article provides a science-forward overview of AOD-9604, what the published research shows, and what Canadian researchers should know when sourcing it through a quality supplier like Helix Core Labs.

What Is AOD-9604?

AOD-9604 — short for Anti-Obesity Drug 9604 — is a synthetic 16-amino acid peptide fragment corresponding to amino acids 176–191 of human growth hormone, with a stabilizing tyrosine substitution at the N-terminus. It was originally developed in the 1990s by Metabolic Pharmaceuticals Ltd. in Australia, with the goal of isolating the lipolytic (fat-mobilizing) activity of hGH while avoiding its growth-promoting and insulin-sensitizing properties.

The key insight behind AOD-9604 was that the C-terminal region of hGH was believed to be responsible for its effects on fat cells, while other regions drive IGF-1 production and bone/muscle growth. By isolating this fragment, researchers hypothesized they could study fat metabolism in a more targeted way.

Mechanism of Action: How AOD-9604 Interacts With Fat Metabolism

The primary mechanism attributed to AOD-9604 in preclinical models involves activation of beta-3 adrenergic receptors on adipocytes (fat cells). When these receptors are stimulated, they activate hormone-sensitive lipase — an enzyme that breaks triglycerides down into free fatty acids and glycerol, which can then be released into the bloodstream and oxidized for energy. This process is called lipolysis.

What distinguishes AOD-9604 from full hGH in research contexts is what it doesn't appear to do:

• It does not appear to significantly elevate IGF-1 levels in preclinical studies
• It does not appear to promote tissue or bone growth
• It does not appear to significantly affect blood glucose or insulin levels

This selectivity makes AOD-9604 interesting to researchers studying isolated metabolic pathways, as it may allow investigation of lipolytic mechanisms without the confounding variables introduced by full growth hormone.

What the Research Says: Preclinical and Clinical Evidence

Preclinical Findings

Early animal studies on AOD-9604 produced notable findings. In studies using obese rodent models, the peptide was reported to significantly reduce body weight gain and increase adipose tissue lipolytic activity. One widely cited preclinical result noted that obese rats treated with AOD-9604 over 19 days showed body weight reductions exceeding 50% compared to controls, alongside measurable increases in lipolytic activity in adipose tissue.

These results sparked interest in translating the research to human models, leading to a series of clinical trials.

Human Clinical Trials

Metabolic Pharmaceuticals conducted six Phase I and Phase II clinical trials of AOD-9604, enrolling approximately 900 participants in total. The trials consistently demonstrated a favorable safety profile — no serious adverse events were attributed to the compound across these studies, suggesting a high tolerability ceiling in human subjects.

However, the clinical picture for efficacy was more nuanced. While early Phase II results showed some promising signals for body composition changes, the larger Phase IIb trial failed to achieve statistical significance for its primary endpoints. Development was discontinued in 2007 as a result.

For researchers, this history is valuable context. AOD-9604 remains a tool for studying metabolic and lipolytic pathways in research settings — and its clinical development history provides a rich dataset for understanding peptide pharmacology, receptor pharmacodynamics, and translational challenges in metabolic drug development.

AOD-9604 and the Canadian Regulatory Landscape

For Canadian researchers working with research peptides, understanding the regulatory context is essential. In Canada, peptides like AOD-9604 that have not received Health Canada approval are not authorized for human therapeutic use or clinical application. They are, however, available for use in legitimate scientific research conducted under appropriate institutional and ethical frameworks.

Research peptides Canada-based suppliers typically provide these compounds explicitly for in vitro studies, academic research, and preclinical investigation — not for personal use or administration. Researchers working within universities, pharmaceutical companies, or approved research institutions should consult their institutional ethics boards and comply with applicable federal and provincial regulations governing the acquisition and use of research biochemicals.

In the United States, AOD-9604 was nominated for the FDA's Bulk Drug Substances list under the 503A compounding framework, though it was ultimately withdrawn from consideration. This regulatory history underscores the importance of sourcing AOD-9604 strictly through legitimate research peptide channels, with full documentation of intended research use.

AOD-9604 vs. Full Growth Hormone: Why Researchers Prefer the Fragment

One of the most common questions in peptide research circles concerns why researchers would study the AOD-9604 fragment rather than full human growth hormone. There are several scientifically meaningful reasons:

• Mechanistic isolation: Studying AOD-9604 allows researchers to examine fat metabolism pathways in isolation, without the growth, insulin, and IGF-1 signals introduced by full hGH
• Receptor specificity: AOD-9604's apparent selectivity for beta-3 adrenergic pathways makes it a useful tool for mapping these receptor-mediated effects
• Cleaner experimental design: By limiting off-target effects, AOD-9604 studies can produce cleaner data when fat metabolism is the primary variable of interest
• Historical dataset: The six completed clinical trials provide a substantial pharmacological and safety database that researchers can reference and build upon

For metabolic researchers studying obesity, adipose biology, or growth hormone receptor pharmacology, AOD-9604 continues to hold scientific value precisely because of — not despite — its developmental history.

What Canadian Researchers Should Look for in a Peptide Supplier

The quality of AOD-9604 used in research settings matters enormously for the integrity of experimental results. Impurities, incorrect concentrations, or poor lyophilization practices can confound data and produce unreliable outcomes. When sourcing AOD-9604 or any research peptide in Canada, researchers should prioritize the following:

Third-Party Testing and Certificates of Analysis

Every batch of research-grade AOD-9604 should be accompanied by a Certificate of Analysis (CoA) from an independent third-party laboratory. The CoA should confirm purity (typically ≥98% for research-grade peptides), molecular mass via mass spectrometry, and HPLC (High-Performance Liquid Chromatography) data confirming the peptide's identity and purity profile. A supplier who cannot provide CoA documentation should not be considered for serious research work.

Lyophilized Format

AOD-9604 should be supplied in lyophilized (freeze-dried) powder form. Lyophilization preserves peptide integrity by removing water that would otherwise facilitate degradation. Liquid pre-mixed peptides are generally unsuitable for rigorous research applications due to reduced shelf life and increased risk of contamination.

Transparent Sourcing and GMP-Adjacent Practices

Reputable suppliers operating within the research peptides Canada market should be transparent about their manufacturing partners, synthesis methods, and quality control procedures. While GMP (Good Manufacturing Practice) certification is typically reserved for pharmaceutical-grade production, research peptide suppliers should demonstrate comparable standards of documentation, environmental control, and batch traceability.

Helix Core Labs: AOD-9604 for Canadian Researchers

At Helix Core Labs, we supply AOD-9604 and a broad catalogue of research peptides to Canadian researchers who demand the highest standards of purity and documentation. Every product in our catalogue is accompanied by independent third-party CoA data, sourced from verified manufacturing partners, and supplied in lyophilized form for optimal research integrity.

Whether you're investigating adipose biology, beta-3 adrenergic receptor pharmacology, or metabolic peptide frameworks, our team is committed to providing research-grade compounds that meet the standards your work demands.

Explore the full Helix Core Labs catalogue to find AOD-9604 and other metabolic peptides for your research program.

All products sold by Helix Core Labs are intended for research use only and are not approved for human or veterinary use. This article is for informational purposes only and does not constitute medical advice.